Literature DB >> 19898184

Angiographic lesion size associated with LOC387715 A69S genotype in subfoveal polypoidal choroidal vasculopathy.

Yoichi Sakurada1, Takeo Kubota, Mitsuhiro Imasawa, Toyoaki Tsumura, Fumihiko Mabuchi, Naohiko Tanabe, Hiroyuki Iijima.   

Abstract

PURPOSE: To investigate whether the LOC387715/ARMS2 variants are associated with an angiographic phenotype, including lesion size and composition, in subfoveal polypoidal choroidal vasculopathy.
METHODS: Ninety-two subjects with symptomatic subfoveal polypoidal choroidal vasculopathy, whose visual acuity was from 0.1 to 0.5 on the Landolt chart, were genotyped for the LOC387715 polymorphism (rs10490924) using denaturing high-performance chromatography. The angiographic phenotype, including lesion composition and size, was evaluated by evaluators who were masked for the genotype. Lesion size was assessed by the greatest linear dimension based on fluorescein or indocyanine green angiography.
RESULTS: Although there was no statistically significant difference in lesion size on indocyanine green angiography (P = 0.36, Kruskal-Wallis test) and in lesion composition (P = 0.59, chi-square test) among the 3 genotypes, there was a statistically significant difference in lesion size on fluorescein angiography (P = 0.0022, Kruskal-Wallis test).
CONCLUSION: The LOC387715 A69S genotype is not associated with lesion composition or size on indocyanine green angiography but with lesion size on fluorescein angiography in patients with subfoveal polypoidal choroidal vasculopathy. Because fluorescein angiography findings represent secondary exudative changes, including subretinal hemorrhages and retinal pigment epithelial detachment, the results in the present study likely indicate that the T allele at the LOC387715 gene is associated with the exudative activity of polypoidal lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898184     DOI: 10.1097/IAE.0b013e3181af0d72

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  13 in total

1.  Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2011-09-29       Impact factor: 2.447

2.  Development of polypoidal lesions in age-related macular degeneration.

Authors:  A Tsujikawa; Y Ojima; K Yamashiro; S Ooto; H Tamura; I Nakata; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

3.  Persons with age-related maculopathy risk genotypes and clinically normal eyes have reduced mesopic vision.

Authors:  Beatrix Feigl; Dingcai Cao; Charles P Morris; Andrew J Zele
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-28       Impact factor: 4.799

4.  Monozygotic twins with polypoidal choroidal vasuculopathy.

Authors:  Shigeki Machida; Tomomi Takahashi; Norimoto Gotoh; Nagahisa Yoshimura; Takamitsu Fujiwara; Dajiro Kurosaka
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Hiroaki Bessho; Shigeru Honda; Naoshi Kondo; Akira Negi
Journal:  Mol Vis       Date:  2011-04-20       Impact factor: 2.367

6.  The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration.

Authors:  Hiroaki Bessho; Shigeru Honda; Naoshi Kondo; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  Mol Vis       Date:  2012-01-18       Impact factor: 2.367

Review 7.  Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis.

Authors:  Haoyu Chen; Ke Liu; Li Jia Chen; Ping Hou; Weiqi Chen; Chi Pui Pang
Journal:  Mol Vis       Date:  2012-04-04       Impact factor: 2.367

8.  Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Seigo Yoneyama; Naohiko Tanabe; Mio Matsubara; Fumihiko Mabuchi; Hiroyuki Iijima
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

9.  Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.

Authors:  Wataru Kikushima; Yoichi Sakurada; Seigo Yoneyama; Atsushi Sugiyama; Naohiko Tanabe; Atsuki Kume; Fumihiko Mabuchi; Hiroyuki Iijima
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

10.  Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Shigeru Honda; Hiroaki Bessho; Naoshi Kondo; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  Mol Vis       Date:  2012-11-22       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.